Abbott Laboratories (ABT Quote) was one of Monday's winners, a day after the company reported positive results from a clinical trial of its Xience drug-coated stent, clearing an important hurdle on the path to Food and Drug Administration approval. Abbott was recently adding $2.07, or 3.8%, to $55.93.
Meanwhile, shares of Boston Scientific (BSX Quote) slid more than 5% after the performance of Abbott's Xience stent was deemed superior to that of Boston Scientific's Taxus stent in a study. Lately, the stock was off 77 cents, or 5.1%, to $14.45.
Osiris Therapeutics (OSIR Quote) jumped after the company reported positive safety and efficacy data on Sunday from a phase I study of its adult stem-cell therapy, Provacel, in patients with heart disease. Osiris was higher by $2, or 11.2%, at $19.90. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,309.92 | 1,091.49 | 2,138.44 | 32.36 |
Oil *
77.05
|
|
DOWN
154.48
|
DOWN
19.14
|
DOWN
37.61
|
UP
0.05
|
10 Yr
3.24%
SPDR Gold
115.06
|
|
-1.48%
|
-1.72%
|
-1.73%
|
+0.15%
|
Data delayed 20 minutes |
Connect with TheStreet